| 26th Apr 2023 10:05 am |
RNS |
Exercise of Options and Total Voting Rights |
| 13th Apr 2023 7:00 am |
RNS |
Audited results for year ended 31 December 2022 |
| 4th Apr 2023 7:00 am |
RNS |
Landmark data published on NTCD-M3 |
| 3rd Apr 2023 7:00 am |
RNS |
Notice of Results and Investor Presentation |
| 24th Mar 2023 7:00 am |
RNS |
Landmark XF-73 Phase 2 data published in journal |
| 16th Mar 2023 3:29 pm |
RNS |
Result of General Meeting and Total Voting Rights |
| 15th Mar 2023 4:02 pm |
RNS |
Result of Open Offer |
| 6th Mar 2023 10:50 am |
RNS |
Exercise of Options and Total Voting Rights |
| 6th Mar 2023 10:31 am |
RNS |
Holding(s) in Company |
| 28th Feb 2023 3:55 pm |
RNS |
Posting of Circular and Notice of General Meeting |
| 27th Feb 2023 4:30 pm |
RNS |
Director/PDMR Shareholding |
| 24th Feb 2023 1:32 pm |
RNS |
Issue of Equity |
| 24th Feb 2023 1:32 pm |
RNS |
Agreement with Sebela Pharmaceutical for NTCD-M3 |
| 24th Feb 2023 11:00 am |
RNS |
Price Monitoring Extension |
| 31st Jan 2023 11:00 am |
RNS |
Price Monitoring Extension |
| 26th Jan 2023 10:10 am |
RNS |
Exercise of Options and Total Voting Rights |
| 25th Jan 2023 7:00 am |
RNS |
US Center for Disease Control review paper |
| 22nd Dec 2022 9:05 am |
RNS |
Second Price Monitoring Extn |
| 22nd Dec 2022 9:00 am |
RNS |
Price Monitoring Extension |
| 22nd Dec 2022 7:00 am |
RNS |
Year End Trading Update |
| 7th Dec 2022 7:00 am |
RNS |
FDA/CDC highlight need for infection preventions |
| 7th Dec 2022 7:00 am |
RNS |
XF-73 Nasal final Phase 3 development plans |
| 2nd Dec 2022 2:48 pm |
RNS |
Director Disclosure |
| 23rd Nov 2022 7:00 am |
RNS |
Appointment of Corporate Broker |
| 21st Nov 2022 2:20 pm |
EQS |
Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections |
| 18th Nov 2022 1:16 pm |
RNS |
Director Shareholding Amendment |
| 15th Nov 2022 7:00 am |
RNS |
XF-73 advances to clinically enabling safety study |
| 31st Oct 2022 11:06 am |
RNS |
Second Price Monitoring Extn |
| 31st Oct 2022 11:01 am |
RNS |
Price Monitoring Extension |
| 22nd Sep 2022 7:00 am |
RNS |
Notice of R&D Update Meeting |
| 8th Sep 2022 7:00 am |
RNS |
Interim results for six months ended 30 June 2022 |
| 7th Sep 2022 7:03 am |
RNS |
Presenting at HC Wainwright Investment Conference |
| 7th Sep 2022 7:01 am |
RNS |
Positive update from EMA on NTCD-M3 Phase 3 plans |
| 5th Sep 2022 2:15 pm |
RNS |
Expiry of Share Options |
| 22nd Aug 2022 7:00 am |
RNS |
Notice of Interim Results |
| 28th Jul 2022 7:00 am |
RNS |
Chair’s Investor Update |
| 26th Jul 2022 7:00 am |
RNS |
Publication of new data on NTCD-M3 |
| 19th Jul 2022 7:00 am |
RNS |
Positive update from US FDA on XF-73 Phase 3 |
| 12th Jul 2022 7:00 am |
RNS |
Grant from the Cystic Fibrosis Foundation |
| 7th Jul 2022 7:00 am |
RNS |
Publication of XF-73 drug synergy data |
